北京
來源：E藥經(jīng)理人
《大國新藥》為什么要做國際版
2021年，《大國新藥》開播。18期節(jié)目，百余位嘉賓，我們記錄了中國創(chuàng)新藥從"跟跑"到"并跑"的每一步。但記錄本身不是目的——當(dāng)科倫博泰與默沙東達成超14億美元合作，當(dāng)百利天恒以84億美元刷新中國Biotech出海紀(jì)錄，我們意識到：中國醫(yī)藥創(chuàng)新的敘事，不能只由中國人來講。更準(zhǔn)確地說：中國醫(yī)藥創(chuàng)新，需要被世界理解；全球醫(yī)藥創(chuàng)新，也需要聽懂中國的聲音。
中國生物醫(yī)藥產(chǎn)業(yè)正在經(jīng)歷一場靜默的范式轉(zhuǎn)移：從"引進來"到"走出去"，License-out交易總額突破千億美元，中國已從全球醫(yī)藥創(chuàng)新的"消費者"變?yōu)?貢獻者"；從"產(chǎn)品出海"到"規(guī)則共建"，當(dāng)中國臨床數(shù)據(jù)成為全球注冊的關(guān)鍵證據(jù)，當(dāng)中國CDMO成為跨國藥企的供應(yīng)鏈核心，"參與規(guī)則制定"比"賣產(chǎn)品"更重要；從"被選擇"到"被需要"，跨國藥企的BD團隊常駐上海、蘇州，不是來"獵取"資產(chǎn)，而是來"共建"生態(tài)。
但對話的鴻溝依然存在。西方產(chǎn)業(yè)界對中國創(chuàng)新的認(rèn)知，仍停留在"成本低、速度快"的刻板印象；中國創(chuàng)新者對全球市場的理解，也常困于"授權(quán)即終點"的路徑依賴。我們需要一個平臺，讓雙方真正聽懂彼此。
在此背景下，《大國新藥》正式推出國際版，由凱萊英醫(yī)藥集團、E藥經(jīng)理人、微解藥、ISWTC聯(lián)合主辦，聚焦醫(yī)藥創(chuàng)新全球化，打造中西方創(chuàng)新者平等對話的專業(yè)平臺。
首發(fā)陣容：五位研發(fā)領(lǐng)袖，一場中西對話
2026年ASCO年會，中國ADC研究入選口頭報告的數(shù)量首次超過美國，多項療效數(shù)據(jù)直接對標(biāo)甚至超越國際標(biāo)桿產(chǎn)品。跨國藥企BD團隊密集約見中國Biotech創(chuàng)始人，談判桌上的核心問題已從"數(shù)據(jù)可靠嗎"變成"全球權(quán)益怎么談"。
但熱潮之下，焦慮才剛剛開始：這是資本寒冬中的"窗口套利"，還是研發(fā)范式與制造能力的系統(tǒng)性崛起？當(dāng)差異化門檻從"有沒有臨床數(shù)據(jù)"升級為"有沒有全球開發(fā)能力"，中國公司準(zhǔn)備好了嗎？
ADC正是回答這些問題的最佳切口——它是中國醫(yī)藥創(chuàng)新"全球化成熟度"最高的賽道，交易活躍、數(shù)據(jù)扎實、產(chǎn)業(yè)生態(tài)完整。更重要的是，ADC的全球化故事映射著整個中國醫(yī)藥創(chuàng)新的未來：從技術(shù)層面的fast-follow到first-in-class躍遷，到產(chǎn)業(yè)層面的單一產(chǎn)品授權(quán)到平臺型合作進化，再到戰(zhàn)略層面的"被選擇"到"規(guī)則共建者"轉(zhuǎn)型。這些議題，不止于ADC，而是中國醫(yī)藥創(chuàng)新全球化的共同命題。
首期節(jié)目將聚焦“中西方視角下的創(chuàng)新、全球化與ADC下一波發(fā)展浪潮”，邀請五位來自中美跨國藥企、Biopharma、Biotech決策者深度對話：
中方嘉賓：
·蔡家強，宜聯(lián)生物聯(lián)合創(chuàng)始人、CSO，Co-CEO
·隋滋野，樂普生物CEO、執(zhí)行董事
國際嘉賓：
·Alexandra Snyder, 默沙東（MSD）腫瘤發(fā)現(xiàn)與轉(zhuǎn)化醫(yī)學(xué)高級副總裁
·Greg Dwyer，Orum Therapeutics 高級副總裁、BD負(fù)責(zé)人
·Anshu Goyal, XYone Therapeutics 聯(lián)合創(chuàng)始人、CEO
主持人：
卓佳旻，EMD Serono全球戰(zhàn)略洞察總監(jiān)
嘉賓簡介向上滑動查看
Jiaqiang Cai
Co-founder & CSO & Co-CEO,
MediLink Therapeutics
Dr. Jiaqiang Cai is Co-Founder, Co-Chief Executive Officer and Chief Scientific Officer of MediLink Therapeutics.
With over 30 years of experience in pharmaceutical R&D, Dr. Cai has authored more than 200 patents and peer reviewed publications. Over 30 compounds developed under his leadership have advanced to clinical research and commercialization stages.
He earned his doctoral degree from the Dalian Institute of Chemical Physics and completed his postdoctoral training at University College London. Prior to founding MediLink, Dr. Cai engaged in innovative drug R&D at Merck Sharp & Dohme, Kelun Pharmaceutical Research Institute and Shanghai Hansoh Pharmaceutical successively.
Ziye Sui
CEO，Executive Director,
Lepu Biopharma
Dr. Ziye Sui, MD/PhD in Neuroscience, is the Chief Executive Officer and Executive Director of Lepu Biopharma, focusing on the discovery and development of innovative oncology therapies with particular expertise in antibody–drug conjugates (ADCs) and immuno oncology. Under her leadership, Lepu Biopharma has built a differentiated pipeline ranging from first in class and best in class ADCs to cutting edge IO agents, with multiple assets advancing through clinical development in China and globally. Dr. Sui combines a rigorous scientific background in neuroscience with extensive industry experience in R&D strategy, clinical development, and business collaboration, and is committed to accelerating the translation of transformative medicines to patients worldwide.
Alexandra Snyder
SVP,Discovery Oncology&
Translational Medicine,
Merck & Co. (MSD)
Alex Snyder, SVP, leads Discovery Oncology and Translational Medicineat Merck, where she is a Senior Vice President. From 2022-2025, she was the Head of Research and Development and Chief Medical Officer at Generate Biomedicines, a biotechnology company that uses artificial intelligence, machine learning and protein engineering to create novel medicines. In this role, Dr. Sryder built the research and development organization, including a portfolio of>20 molecules in diverse indications and modalities, and initiation of 4 clinical trials across 3 new molecular entities. Prior to joining Generate, Dr. Snyder was a Principal at the biotech incubator Two River following her role as Associate Vice President and Head of Translational Oncology at Merck. She previously was Translational Medicine Lead at Adaptive Bioteechnologies, and started her career as faculty and federally-funded Principal Investigator at Memorial Sloan Kettering Cancer Center. Dr. Snyder is a Cancer Steering Committee(CSC)Biomedical Co-Chair for the Executive Committee of the FNIH and co-leads the SITC Biomarker Working Group. She is a Clinical Assistant Professor of Medicine at NYU and Bellevue Hospitals,Section Editor for the Journal for the Immunotherapy of Cancer, and was a member of the board of Navigating Cancer. Dr.Snyder received her medical degree and internal medicine training at the Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, followed by medical oncology fellowship at Memorial Sloan Kettering Cancer Center(MSKCC).
Greg Dwyer
SVP, Head of BD,
Orum Therapeutics
Greg Dwyer is Senior Vice President and Head of Business Development at Orum Therapeutics, where he is responsible for licensing the company’s discovery platforms and development programs. He brings expertise in BD&L and strategy at growth-stage biotechnology companies, with a focus on oncology, antibody-drug conjugates, and protein degradation.
Prior to joining Orum, Greg held business development leadership roles at Magenta Therapeutics and ImmunoGen. At Magenta, he worked on business development and operational aspects of targeted conditioning programs, including MGTA-117, and supported strategic relationships for research and CMC activities. At ImmunoGen, his work covered licensing of the company’s proprietary antibody-drug conjugate platform for target-specific oncology drug discovery, pipeline asset partnering, complementary technology scouting,and biomarker/CDx collaborations.
Earlier in his career, Greg gained experience in pharmaceutical consulting at Decision Resources and discovery chemistry at Bristol-Myers Squibb. He holds an MBA in Operations, Finance, and Strategy from the Boston College Carroll School of Management.
Anshu Goyal
CEO &Co-Founder,
XYone Therapeutics
Anshu Goyal is the CEO & Co-Founder of Xyone Therapeutics and has supported early-stage research and development in hormonal dysregulation for over a decade. With experience spanning both biotechnology innovation and strategic investment, he previously led investment teams at major hedge funds including Millennium and Exodus Partners during his Wall Street career.
He brings a cross-disciplinary perspective on biotech innovation, translational development, and the evolving landscape of next-generation therapeutics.
主持人：
Jiamin Zhuo
Director, global strategy insights,
EMD Serono
Jiamin Zhuo, Ph.D., is a seasoned professional with a diverse background spanning scientific research, Wall Street equity analysis, and commercial strategy in biopharma. His career includes impactful roles at Decision Resources Group, Guggenheim Investment Bank, and commercial positions at Takeda and bit.bio., an innovative iPSC cell therapy biotech, where he shaped strategies for drug development and commercial pathway. Currently, he serves as Global Strategy Insight Director at EMD Serono, focusing on optimizing drug potential and driving commercial growth.
Beyond his corporate work, Jiamin co-founded InScienceWeTrust Community (ISWTC), a not-for-profit organization supporting the Asian Biotech ecosystem, and edits its Weekly Newsletter, which reaches over 6,000 subscribers. He holds a BS from Peking University, a Ph.D. from Mayo Clinic, and completed post-graduate training at Boston University and MIT. Passionate about bridging science and business, Jiamin is dedicated to advancing innovation and fostering collaboration in the biopharmaceutical industry.
特別聲明：以上內(nèi)容(如有圖片或視頻亦包括在內(nèi))為自媒體平臺“網(wǎng)易號”用戶上傳并發(fā)布，本平臺僅提供信息存儲服務(wù)。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
